NCT07467447招募中2 期
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Hudson Biotech1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年2月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Mean percent change in body weight from randomization/baseline to Week 24.
研究概览
简要总结
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
详细描述
After screening (up to 6 weeks), eligible participants are randomized to one of several dose-escalation regimens leading to maintenance doses of 1, 4, 8, or 12 mg retatrutide (or placebo) administered once weekly for 48 weeks, followed by a 4-week safety follow-up. Two maintenance dose levels (4 mg and 8 mg) include alternative escalation schedules to evaluate tolerability. The primary efficacy evaluation is at Week 24 (percent change in body weight), with additional weight, anthropometric, and safety assessments through Week 48.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
To preserve blinding, placebo participants follow an injection dose-escalation schedule matched to one of the active retatrutide arms.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years (inclusive) at time of informed consent.
- •BMI ≥30 and ≤50 kg/m², OR BMI ≥27 and <30 kg/m² with at least 1 weight-related comorbidity (hypertension; dyslipidemia; or cardiovascular disease such as ischemic CVD or NYHA Class I-II heart failure).
- •Motivated and able/willing to self-inject (or have trained assistance if needed) and follow study procedures, including lifestyle advice and questionnaires.
- •Subgroup (NAFLD addendum): liver fat content ≥10% by MRI-PDFF (for participants invited to the addendum).
- •Male and/or female; contraception requirements apply; women of childbearing potential must have negative pregnancy tests at specified visits and should not be breastfeeding.
- •Capable of giving signed informed consent and complying with protocol requirements.
排除标准
- •History of diabetes mellitus (type 1 or type 2), ketoacidosis, or hyperosmolar state/coma.
- •Screening lab values suggestive of diabetes (HbA1c ≥6.5%; fasting glucose ≥126 mg/dL; or random glucose ≥200 mg/dL).
- •Self-reported change in body weight >5 kg within 3 months prior to screening.
- •Prior or planned surgical treatment for obesity (exceptions: liposuction/abdominoplasty >1 year prior).
- •Current/planned endoscopic or device-based obesity therapy, or device removal within last 6 months (e.g., intragastric balloon, gastric artery embolization).
- •Renal impairment: eGFR <45 mL/min/1.73 m² (CKD-EPI) at screening.
- •Clinically significant gastric emptying abnormality (e.g., severe gastroparesis) or chronic drugs affecting GI motility.
- •History of acute or chronic pancreatitis (exception for resolved gallstone pancreatitis post-cholecystectomy).
- •TSH outside 0.4 to 6.0 mIU/L at screening (with protocol-defined exceptions).
- •Obesity due to other endocrine disorders (e.g., Cushing's) or monogenic/syndromic obesity (e.g., Prader-Willi).
- •Psychiatric exclusion criteria including unstable major depressive disorder/severe psychiatric disorder within 2 years; lifetime suicide attempt; PHQ-9 score ≥15; or specified Columbia-Suicide Severity Rating Scale (C-SSRS) findings within past month.
- •Uncontrolled hypertension (systolic ≥160 mmHg and/or diastolic ≥100 mmHg) or elevated resting pulse rate (>100 bpm) at baseline.
- •Recent (within 3 months) major cardiovascular events (e.g., MI, stroke, unstable angina, CHF hospitalization); tachyarrhythmia syndromes; NYHA Class III-IV CHF; or ECG abnormalities interfering with interpretation.
- •Acute/chronic hepatitis or liver disease other than NAFLD; or screening labs: ALT >3× ULN, ALP >1.5× ULN, or total bilirubin >1.5× ULN (with exception).
- •Elevated calcitonin at Visit 1 per protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN
- •Active/untreated malignancy or remission <5 years (with protocol exceptions for certain in-situ/skin cancers).
- •Contraindication to GLP-1 receptor agonists, or other conditions that could prevent protocol compliance (including drug/alcohol abuse or eating disorder), per investigator judgment.
- •Alcohol consumption >14 units/week (women) or >21 units/week (men).
- •Recent marijuana/THC-containing product use within 3 months or unwillingness to abstain during trial (protocol exception for cannabidiol oil if agrees to refrain).
- •Organ transplant history (except corneal transplant) or awaiting transplant.
- •Hematologic conditions interfering with HbA1c measurement; recent large blood donation/transfusion/severe blood loss; hemoglobin below protocol thresholds.
- •Severe atopy/multiple severe allergies or severe hypersensitivity reactions.
- •Fasting triglycerides >500 mg/dL at screening (with stability requirement for lipid-lowering therapy).
- •Significant active, uncontrolled medical condition or history posing risk or interfering with data interpretation, per investigator judgment.
- •History of symptomatic gallbladder disease within past 2 years (protocol-defined exceptions after cholecystectomy).
- •History of documented HIV infection.
- •Chronic systemic glucocorticoid therapy within 3 months or active autoimmune abnormality likely to require systemic steroids during study (with specified formulation exceptions).
- •Recent medications that may cause significant weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, mood stabilizers) within 3 months.
- •Recent use (within 3 months) of medications or remedies intended to promote weight loss (examples listed in protocol, including GLP-1 RAs).
- •Use of metformin or other glucose-lowering medications (e.g., for PCOS or diabetes prevention) not permitted at entry.
- •Started implantable/injectable contraceptives within 18 months prior to screening (IUDs allowed if used ≥3 months).
- •Known allergies to GLP-1 receptor agonists or LY
- •Currently enrolled in another investigational study or recent participation/treatment within 30 days (or 5 half-lives, whichever longer).
- •Previously received LY3437943 in this or another study.
- •Investigator site personnel directly affiliated with the study and/or their immediate family; or Lilly employees.
- •Note: The publicly posted protocol references additional exclusion criteria numbered 52-57 in a separate protocol addendum (not included in the posted protocol PDF).
研究组 & 干预措施
Retatrutide (LY3437943) 1 mg once weekly (no escalation)
Experimental
干预措施: Placebo (Drug)
Retatrutide (LY3437943) 1 mg once weekly (no escalation)
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide (LY3437943) 1 mg once weekly (no escalation)
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.
Experimental
干预措施: Placebo (Drug)
Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).
Experimental
干预措施: Placebo (Drug)
Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg
Experimental
干预措施: Placebo (Drug)
Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.
Experimental
干预措施: Placebo (Drug)
Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Placebo once weekly (matched escalation schedule to maintain blinding).
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Placebo once weekly (matched escalation schedule to maintain blinding).
Experimental
干预措施: Placebo (Drug)
Placebo once weekly (matched escalation schedule to maintain blinding).
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.
Experimental
干预措施: Retatrutide (LY3437943) (Drug)
Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.
Experimental
干预措施: Placebo (Drug)
Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.
Experimental
干预措施: Standardized diet and physical activity counseling throughout the study. (Behavioral)
结局指标
主要结局
Mean percent change in body weight from randomization/baseline to Week 24.
时间窗: 24 weeks
次要结局
- Safety and tolerability outcomes (e.g., treatment-emergent adverse events; serious adverse events; discontinuations due to adverse events).(48 weeks)
- Mean percent change in body weight from baseline to Week 48(48 weeks)
- Proportion of participants achieving ≥5%, ≥10%, and ≥15% body weight reduction at Weeks 24 and 48.(48 weeks)
- Mean change in body weight (kg) at Weeks 24 and 48.(48 weeks)
- Mean change in BMI (kg/m²) at Weeks 24 and 48.(48 weeks)
- Mean change in waist circumference (cm) at Weeks 24 and 48(48 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisNCT07415044Eli Lilly and Company1,431
招募中
3 期
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsNCT07382167Ardelyx692
Unknown
3 期
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and or Serious InfectionsCTRI/2025/02/080276Novotech Clinical Research India Private Limited150
尚未招募
2 期
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeNCT07375524Shanghai Escugen Biotechnology Co., Ltd40
进行中（未招募）
2 期
Taldefgrobep Alfa in Adults With Overweight and ObesityObesityNCT07281495Biohaven Therapeutics Ltd.150